PMID- 10361239
OWN - NLM
STAT- MEDLINE
DCOM- 19990623
LR  - 20190513
IS  - 0009-9104 (Print)
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 116
IP  - 3
DP  - 1999 Jun
TI  - Immunological changes in peripheral blood and in lymphoid tissue after treatment 
      of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or 
      HAART + IL-2.
PG  - 486-92
AB  - This study presents the immunophenotypic and functional analysis of lymphocyte 
      subsets obtained from peripheral blood and lymphoid tissue from HIV+ individuals 
      treated with highly active anti-retroviral therapy (HAART) alone or in 
      combination with 6 million units international (MUI) s.c. IL-2. Before treatment, 
      the HIV+ patients had reduced CD4 and increased CD8 values in the peripheral 
      blood and lymphoid tissue and impaired cytokine production by peripheral blood 
      mononuclear cells (PBMC). After 24 weeks of treatment, all the HIV+ patients 
      demonstrated increased CD4 values in peripheral blood and lymphoid tissue. The 
      use of IL-2 did not promote an additional CD4 expansion compared with HAART 
      alone; increased 'naive' and CD26+ CD4 cells and reduced CD8 cells were found in 
      the peripheral blood and lymphoid tissue of the IL-2-treated, but not of the 
      HAART-treated patients. Both types of treatment induced a significant reduction 
      of the CD8/CD38+ cells. While HAART alone had negligible effects on cytokine 
      production by PBMC, the combined use of HAART + IL-2 was unable to increase the 
      endogenous production of IL-2, but caused an increase of IL-4, IL-13 and 
      interferon-gamma (IFN-gamma) and a reduction of monocyte chemoattractant 
      protein-1 (MCP-1) production. These data suggest that, although in this schedule 
      IL-2 has minimal efficacy on CD4 recovery when compared with HAART alone, it 
      produces an increase of 'naive' and CD26+ CD4 cells and a partial restoration of 
      cytokine production. These data may be used to better define clinical trials 
      aiming to improve the IL-2-dependent immunological reconstitution of HIV-infected 
      subjects.
FAU - Zanussi, S
AU  - Zanussi S
AD  - Department of Microbiology, Immunology & Virology, Centro di Riferimento 
      Oncologico IRCCS, Aviano, Ospedale di Pordenome, Italy.
FAU - Simonelli, C
AU  - Simonelli C
FAU - Bortolin, M T
AU  - Bortolin MT
FAU - D'Andrea, M
AU  - D'Andrea M
FAU - Crepaldi, C
AU  - Crepaldi C
FAU - Vaccher, E
AU  - Vaccher E
FAU - Nasti, G
AU  - Nasti G
FAU - Politi, D
AU  - Politi D
FAU - Barzan, L
AU  - Barzan L
FAU - Tirelli, U
AU  - Tirelli U
FAU - De Paoli, P
AU  - De Paoli P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/*therapeutic use
MH  - CD4 Lymphocyte Count
MH  - CD4-CD8 Ratio
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cytokines/biosynthesis
MH  - Female
MH  - HIV Infections/*drug therapy/immunology/*therapy
MH  - Humans
MH  - In Vitro Techniques
MH  - Interleukin-2/*therapeutic use
MH  - Lymphoid Tissue/immunology
MH  - Male
MH  - Middle Aged
MH  - Phenotype
PMC - PMC1905321
EDAT- 1999/06/11 00:00
MHDA- 1999/06/11 00:01
PMCR- 2000/06/01
CRDT- 1999/06/11 00:00
PHST- 1999/06/11 00:00 [pubmed]
PHST- 1999/06/11 00:01 [medline]
PHST- 1999/06/11 00:00 [entrez]
PHST- 2000/06/01 00:00 [pmc-release]
AID - 10.1046/j.1365-2249.1999.00927.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 1999 Jun;116(3):486-92. doi: 10.1046/j.1365-2249.1999.00927.x.